Anja Smits

Summary

Affiliation: Uppsala University
Country: Sweden

Publications

  1. pmc Perfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas
    Shala Ghaderi Berntsson
    Department of Neuroscience, Neurology, Uppsala University, University Hospital, Sweden
    J Neurooncol 114:241-9. 2013
  2. pmc The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II
    Anja Smits
    Department of Neuroscience, Neurology, University Hospital, Uppsala University, 751 85 Uppsala, Sweden
    Int J Mol Imaging 2011:372509. 2011
  3. pmc PROX1 is a predictor of survival for gliomas WHO grade II
    T Elsir
    Department of Oncology Pathology, Karolinska Institutet, CCK R8 05, Karolinska University Hospital, S 17176 Stockholm, Sweden
    Br J Cancer 104:1747-54. 2011
  4. pmc GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome
    Anja Smits
    Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden
    PLoS ONE 7:e37041. 2012
  5. doi request reprint Seizures and the natural history of World Health Organization Grade II gliomas: a review
    Anja Smits
    Department of Neuroscience and Neurology, Uppsala University, University Hospital, Uppsala, Sweden
    Neurosurgery 68:1326-33. 2011
  6. ncbi request reprint Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors
    Zhi Ping Ren
    Department of Genetics and Pathology, Uppsala University, University Hospital, Uppsala, Sweden
    J Neuropathol Exp Neurol 66:944-54. 2007
  7. pmc Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker
    Daniel Hägerstrand
    Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, S 171 76 Stockholm, Sweden
    Neuro Oncol 10:2-9. 2008
  8. doi request reprint A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival
    Tamador Elsir
    Department of Neuroscience, Neurology, Uppsala University, University Hospital, S 751 85, Uppsala Karolinska Institute, Department of Oncology Pathology, CCK R8 05, Karolinska University Hospital, S 17176, Stockholm, Sweden
    Int J Cancer 134:1123-31. 2014
  9. doi request reprint Subtyping of gliomas of various WHO grades by the application of immunohistochemistry
    Svetlana N Popova
    Department of Pathology and Cytology, Uppsala University Hospital, Uppsala, Sweden
    Histopathology 64:365-79. 2014
  10. doi request reprint Transcription factor PROX1: its role in development and cancer
    Tamador Elsir
    Department of Oncology Pathology, Karolinska Institutet, CCK R8 05, Karolinska University Hospital, 17176 Stockholm, Sweden
    Cancer Metastasis Rev 31:793-805. 2012

Collaborators

Detail Information

Publications24

  1. pmc Perfusion and diffusion MRI combined with ¹¹C-methionine PET in the preoperative evaluation of suspected adult low-grade gliomas
    Shala Ghaderi Berntsson
    Department of Neuroscience, Neurology, Uppsala University, University Hospital, Sweden
    J Neurooncol 114:241-9. 2013
    ....
  2. pmc The Clinical Value of PET with Amino Acid Tracers for Gliomas WHO Grade II
    Anja Smits
    Department of Neuroscience, Neurology, University Hospital, Uppsala University, 751 85 Uppsala, Sweden
    Int J Mol Imaging 2011:372509. 2011
    ..As such, spatial changes in tumor activity over time, including shifts of hot-spot regions within the tumor, may reflect intratumoral heterogeneity and correlate to clinical parameters...
  3. pmc PROX1 is a predictor of survival for gliomas WHO grade II
    T Elsir
    Department of Oncology Pathology, Karolinska Institutet, CCK R8 05, Karolinska University Hospital, S 17176 Stockholm, Sweden
    Br J Cancer 104:1747-54. 2011
    ..We have recently shown that PROX1 may act as a diagnostic marker for high-grade gliomas. The aim of this study was to address the prognostic value of PROX1 in grade II gliomas...
  4. pmc GABA-A channel subunit expression in human glioma correlates with tumor histology and clinical outcome
    Anja Smits
    Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden
    PLoS ONE 7:e37041. 2012
    ..Our data give support for the presence of distinct GABA-A channel subtypes in gliomas and provide the first link between specific composition of the A-channel and patient survival...
  5. doi request reprint Seizures and the natural history of World Health Organization Grade II gliomas: a review
    Anja Smits
    Department of Neuroscience and Neurology, Uppsala University, University Hospital, Uppsala, Sweden
    Neurosurgery 68:1326-33. 2011
    ..Despite the frequency of seizures as initial symptoms and symptoms of later disease, seizures in relation to the natural course of low-grade gliomas have received little attention...
  6. ncbi request reprint Molecular genetic analysis of p53 intratumoral heterogeneity in human astrocytic brain tumors
    Zhi Ping Ren
    Department of Genetics and Pathology, Uppsala University, University Hospital, Uppsala, Sweden
    J Neuropathol Exp Neurol 66:944-54. 2007
    ..Our results are of importance for a further understanding of the molecular mechanisms behind failure to treat glioma patients...
  7. pmc Gene expression analyses of grade II gliomas and identification of rPTPbeta/zeta as a candidate oligodendroglioma marker
    Daniel Hägerstrand
    Department of Oncology and Pathology, Cancer Center Karolinska, Karolinska Institutet, S 171 76 Stockholm, Sweden
    Neuro Oncol 10:2-9. 2008
    ..Furthermore, the results from the immunohistochemical analyses of rPTPbeta/zeta expression should prompt further evaluation of this protein as a novel oligodendroglioma marker...
  8. doi request reprint A study of embryonic stem cell-related proteins in human astrocytomas: identification of Nanog as a predictor of survival
    Tamador Elsir
    Department of Neuroscience, Neurology, Uppsala University, University Hospital, S 751 85, Uppsala Karolinska Institute, Department of Oncology Pathology, CCK R8 05, Karolinska University Hospital, S 17176, Stockholm, Sweden
    Int J Cancer 134:1123-31. 2014
    ..These findings provide further evidence for the joint regulatory pathways of ESC-related proteins in gliomas and identify Nanog as one of the key players in determining clinical outcome of human astrocytomas. ..
  9. doi request reprint Subtyping of gliomas of various WHO grades by the application of immunohistochemistry
    Svetlana N Popova
    Department of Pathology and Cytology, Uppsala University Hospital, Uppsala, Sweden
    Histopathology 64:365-79. 2014
    ..The objective of this study was to assess whether gliomas, independently of the type and grade, could be subdivided into protein-based subtypes...
  10. doi request reprint Transcription factor PROX1: its role in development and cancer
    Tamador Elsir
    Department of Oncology Pathology, Karolinska Institutet, CCK R8 05, Karolinska University Hospital, 17176 Stockholm, Sweden
    Cancer Metastasis Rev 31:793-805. 2012
    ..This review provides an update on the role of PROX1 in organ development and on its emerging functions in cancer, with special emphasis on the central nervous system and glial brain tumors...
  11. ncbi request reprint DLG3/SAP102 protein expression in malformations of cortical development: a study of human epileptic cortex by tissue microarray
    Mingqi Qu
    Department of Neuroscience, Neurology, Uppsala University Hospital, Sweden
    Epilepsy Res 84:33-41. 2009
    ..Our results suggest a putative role for DLG3/SAP102 in cortical hyperexcitability and epileptogenicity of malformations of cortical development...
  12. ncbi request reprint A family with discordance between malignant hyperthermia susceptibility and rippling muscle disease
    Jimmy Sundblom
    Department of Neuroscience, Neurology, University Hospital, Uppsala University, 751 85, Uppsala, Sweden
    J Anesth 27:128-31. 2013
    ..We conclude that RMD patients should not, on the basis of our present knowledge, be classified as having MHS; however, an increased surveillance for MH reactions is recommended in these patients...
  13. ncbi request reprint Time-course and determinants of spasticity during the first six months following first-ever stroke
    Erik Lundström
    Department of Neuroscience, Neurology and Rehabilitation Medicine, Uppsala University Hospital, Uppsala, Sweden
    J Rehabil Med 42:296-301. 2010
    ..To explore the occurrence of, and risk factors for, spasticity until 6 months after first-ever stroke...
  14. ncbi request reprint Baseline 11C-methionine PET reflects the natural course of grade 2 oligodendrogliomas
    Dan Ribom
    Department of Neuroscience, Neurology, University Hospital, SE 751 85 Uppsala, Sweden
    Neurol Res 27:516-21. 2005
    ..The aim of the present study was to assess the usefulness of positron emission tomography (PET) with the amino acid tracer 11C-methionine (MET) as a predictor of time to progression (TTP) in patients with supratentorial grade 2 gliomas...
  15. pmc Pathological neural attractor dynamics in slowly growing gliomas supports an optimal time frame for white matter plasticity
    Krisztina Szalisznyó
    Department of Neuroscience, Neurology, Uppsala University, Uppsala, Sweden
    PLoS ONE 8:e69798. 2013
    ....
  16. doi request reprint Tumor-associated epilepsy and glioma: are there common genetic pathways?
    Shala Ghaderi Berntsson
    Department of Neuroscience, Neurology, University Hospital Uppsala, Uppsala, Sweden
    Acta Oncol 48:955-63. 2009
    ..It is likely that the variability in epileptic symptoms cannot exclusively be explained by tumor-related factors, but rather reflects complex interaction between tumor-related, environmental and hereditary factors...
  17. ncbi request reprint On the issue of early and aggressive treatment in grade 2 gliomas
    Dan Ribom
    Department of Neuroscience, University Hospital, 751 85 Uppsala, Sweden
    J Cancer Res Clin Oncol 129:154-60. 2003
    ..To study the effects of surgery and timing of radiotherapy on patient survival in grade 2 gliomas...
  18. ncbi request reprint Evaluation of 11C-methionine PET as a surrogate endpoint after treatment of grade 2 gliomas
    Dan Ribom
    Department of Neuroscience, Neurology, University Hospital, Uppsala, Sweden
    J Neurooncol 71:325-32. 2005
    ..PET MET may be a promising surrogate endpoint after treatment of grade 2 gliomas. Evaluation of both hot spot activity and uptake volume on PET may strengthen the association with clinical outcome...
  19. pmc Mast cell accumulation in glioblastoma with a potential role for stem cell factor and chemokine CXCL12
    Jelena Polajeva
    Rudbeck Laboratory, Department of Immunology, Genetics and Pathology, Uppsala University, Uppsala, Sweden
    PLoS ONE 6:e25222. 2011
    ..Moreover, human GBMs were positive for CXCL12 and the infiltrating MCs were positive for CXCR4. In conclusion, we provide the first evidence for a role for MCs in glioma...
  20. ncbi request reprint Genetically distinct astrocytic and oligodendroglial components in oligoastrocytomas
    Mingqi Qu
    Department of Genetics and Pathology, University Hospital Uppsala, 751 85, Uppsala, Sweden
    Acta Neuropathol 113:129-36. 2007
    ....
  21. doi request reprint Analysis of DNA repair gene polymorphisms and survival in low-grade and anaplastic gliomas
    Shala Ghaderi Berntsson
    Department of Neuroscience, Neurology, University Hospital, 75185 Uppsala, Sweden
    J Neurooncol 105:531-8. 2011
    ..184, 95% CI 0.054-0.63, P = 0.007). We suggest a possible novel association between rs4253079 and survival in this group of patients with low-grade and anaplastic gliomas that needs confirmation in larger datasets...
  22. ncbi request reprint Elevated levels of alpha-2-Heremans-Schmid glycoprotein in CSF of patients with low-grade gliomas
    Dan Ribom
    Department of Neuroscience, Neurology, University Hospital, Uppsala, Sweden
    Tumour Biol 24:94-9. 2003
    ..Further analyses are planned to determine the significance of the increased levels of AHSG in the CSF of patients with low-grade gliomas...
  23. ncbi request reprint Bedside diagnosis of rippling muscle disease in CAV3 p.A46T mutation carriers
    Jimmy Sundblom
    Department of Neuroscience, Neurology, University Hospital, Uppsala University SE 751 85 Uppsala, Sweden
    Muscle Nerve 41:751-7. 2010
    ..The presence of PIMM and PIRC seems to be diagnostic at all ages, whereas the absence of hyperCKemia and rippling does not exclude the diagnosis...
  24. doi request reprint Four-fold increase in direct costs of stroke survivors with spasticity compared with stroke survivors without spasticity: the first year after the event
    Erik Lundström
    Departments of Neuroscience, Neurology and Rehabilitation Medicine, Uppsala University Hospital, Uppsala, Sweden
    Stroke 41:319-24. 2010
    ..The objective of our study was to estimate direct costs of stroke with spasticity for patients surviving up to 1 year after the stroke event in comparison to costs of stroke without spasticity...